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A series of mono- and dinuclear (η6-arene) ruthenium(II) complexes were prepared by reaction of
thiosemicarbazone ligands derived from benzaldehyde and ruthenium(II) precursors of the general formula
[Ru(η6-arene)(μ-Cl)Cl]2, where arene=p-iPrC6H4Me or C6H5C3H6COOH. These complexes were characterized
by NMR and IR spectroscopy, ESI-mass spectrometry and elemental analysis. The molecular structure of the
mononuclear p-cymene complex was determined by X-ray diffraction analysis, revealing a pseudo-
tetrahedral piano stool conformation and a bidentate N,S coordination mode of the thiosemicarbazone
ligand. The complexes and ligands were evaluated for their in vitro cytotoxicity against the WHCO1
oesophageal cancer cell line.
Metal-based therapeutic agents have been used as anticancer drugs
in recent years [1]. Drugs speciﬁcally derived from platinum, have been
used extensively as anticancer agents. The benchmark discovery of the
anticancer properties of cis-diamminedichloroplatinum(II) (cisplatin)
was made by Rosenberg and co-workers in the mid 1960's [2]. This
discovery single-handedly propelled research based on using metal-
containing compounds as anticancer agents [2]. To date, cisplatin is
considered to be one of the most effective and widely used anticancer
drugs. Second generation platinum drugs including carboplatin and
oxaliplatin have been developed for clinical application [3].
The efﬁcacy of these drugs, including cisplatin, however, is reduced
by increasing tumour resistance and in the case of cisplatin, high
toxicity. This in turn affects the administration of the drugs [4–8]. These
limitations have aroused interest towards the design and evaluation of
transition metal complexes other than platinum-based derivatives for
therapeutic use. In recent years, several ruthenium-based complexes
have been investigated for potential antitumor activity. Two ruthenium
(III) complexes namely [indH]trans-[Ru(N-ind)2Cl4] (KP1019) [9–11]
and [imiH]trans-[Ru(N-imi)(S-dmso)Cl4] (NAMI-A) [12,13] (imi=imi-
dazole and ind=indazole) have successfully completed phase I clinical
trials.
Half-sandwich arene ruthenium(II) complexes have generated
great interest as potential anticancer agents. Many mono- and
polynuclear arene ruthenium(II) compounds have displayed in vitro
and/or in vivo antiproliferative activity [14–18]. Complexes of the
general formula [Ru(η6-arene)(en)Cl]PF6, (where en=ethylenedia-
mine and arene=benzene, p-cymene, tetrahydroanthracene, dihy-
droanthracene and biphenyl) have also exhibited anticancer activity.
This included activity against cisplatin-resistant cells [19,20]. More
recently, a series of arene ruthenium(II) complexes containing 1,3,5-
triaza-7-phosphaadamantane (PTA) derivatives were evaluated for
their activity [21–25].
Thiosemicarbazones (TSCs) are versatile ligands as they possess a
number of donor atoms which may coordinate in various ways. In
addition to this, thiosemicarbazones possess a variety of biological
properties including antiproliferative activity [26]. Studies have
demonstrated that TSCs are potent inhibitors of the enzyme
ribonucleotide reductase (RR) and are capable of interrupting DNA
synthesis and repair [27]. Incorporation of metals onto these TSC
ligands can result in alteration or enhancement of their biological
activity [28]. In a recent study, half-sandwich (η6-p-cymene)
ruthenium(II) complexes derived from bidentate thiosemicarbazones
were evaluated for their biological activity against breast and
colorectal carcinoma cells. The complexes exhibited good in vitro
cytotoxic activity against all cancer cell lines [29]. Our previous work
regarding the anticancer activity of dithiosemicarbazone palladium
(II) complexes has been problematic due to the poor solubility of
these compounds [30]. Many arene ruthenium complexes have been
known to possess good biological activity as well as solubility in
aqueous media. This paper reports the synthesis, characterization and
cytotoxicity of half-sandwich (η6-arene) ruthenium(II) complexes of
benzaldehyde derived mono- and dithiosemicarbazones.
The benzaldehyde monothiosemicarbazone (L1) was prepared by
modiﬁcation of the literature method [31]. Benzene-1,4-dithiosemi-
carbazide was prepared according to the reported procedure [32] and
⁎ Corresponding author. Tel.: +27 21 650 5279; fax: +27 21 650 5195.
E-mail address: gregory.smith@uct.ac.za (G.S. Smith).
, ,
1
subsequently reﬂuxed with benzaldehyde in a 1:2 stoichiometric ratio in
MeOH affording the desired dithiosemicarbazone ligand (L2) in 91% yield
[33]. Complexes 1 and 2 were prepared by reaction of L1 and [Ru(η6-p-
cymene)(μ-Cl)Cl]2 [34] or [Ru(η6-C6H5C3H6COOH)(μ-Cl)Cl]2 [35] in a 2:1
molar ratio (Scheme 1). Complexes 3 and 4were obtained by reaction of
L2 and [Ru(η6-p-cymene)(μ-Cl)Cl]2 or [Ru(η6-C6H5C3H6COOH)(μ-Cl)Cl]2
using a 1:1 molar ratio (Scheme 2). All reactions were carried out by
stirring the contents at ambient temperature for 16–24 h. All complexes
were obtained as air-stable red/orange solids in moderate to good yields
(62–89%) [36]. Complexes1 and3 are readily soluble and stable in CH2Cl2,
CHCl3, MeOH, EtOH and DMSO and sparingly soluble in water, while
complexes 2 and 4 are less soluble in chlorinated solvents.
All compounds were characterized using NMR and IR spectroscopy,
ESI-mass spectrometry and elemental analysis. The 1HNMRspectrumof
L2displays a signal for the imineprotons at8.52 ppmanda signal for the
hydrazinic protons at 12.06 ppm. The protons of the phenyl bridge
appear as a singlet at 7.92 ppm attesting to the symmetrical nature of
themolecule. The 1HNMR spectra of the complexes (1–4) suggest a loss
of the two-fold symmetry of the p-cymene and the carboxylic acid arene
ligands upon coordination of the metal to the thiosemicarbazone
ligands. In these complexes the ruthenium atoms are stereogenic due to
the coordination of four different ligator atoms. The loss of symmetry is
evidenced by the appearance of a set of four doublets in the region of
4.60 and 5.40 ppm accounting for the protons of the p-cymene rings of
complexes 1 and 3. The methyl substituents of the isopropyl group are
observed as two distinct doublets in the aliphatic region of the spectra,
which further conﬁrms the loss of symmetry as the two methyl groups
are non-equivalent. These methyl protons are observed at 1.07 and
1.13 ppm for complex 1 and at 1.09 and 1.15 ppm for complex 3. In the
case of the carboxylic acid derivatives (2 and 4), three pseudo-triplets
and two doublets are observed for the arene ring and are found in the
region of 5.00–5.50 ppm. The loss of symmetry of the arene rings in all
cases suggests that these complexes have similarmodesof coordination.
Singlets for the imineprotons are observed at 9.05 (1), 8.81 (2), 9.04 (3),
and 8.90 ppm (4). A downﬁeld shift is observed for these signals
compared to the free ligands upon coordination to ruthenium,
suggesting coordination of the metal to the azomethine nitrogen atom
as the signal becomes more deshielded in each case. This is also
observed for similar arene ruthenium(II) thiosemicarbazone complexes
[29,37].
The infrared spectrum of L2 displays absorption bands at 1600 and
860 cm−1 for the C=N and C=S stretching frequencies, respectively.
The infrared spectra of the complexes suggest that the thiosemicarba-
zones act as neutral ligands upon coordination. The metals are
coordinated to the ligands via the imine nitrogen and the thione sulfur
atoms. Absorption bands for the azomethine stretching frequencies
(νC=N) of complexes 1 and 3 are observed at approximately 1618 and
1614 cm−1, respectively. This particular band is found at approximately
1600 cm−1 for complexes 2 and 4. Bands for the thione stretching
frequencies (νC=S) are observed in the region of 845–875 cm−1. The IR
spectra of complexes 2 and 4 display absorption bands for the carbonyl
stretching frequencies (νC=O) at 1698 and 1727 cm−1, respectively.
The ESI mass spectra display base peaks corresponding to the
fragment [M-HCl-Cl]+ for complexes 1 and 2. A peak of 85% intensity
corresponding to the fragment [M-4HCl-H+2Na]+ is observed for
complex 3, while a fragment corresponding to [M-2Cl-CO2]+ is
observed for complex 4. Elemental analysis further conﬁrms the
composition of these compounds. The data obtained for these
complexes are consistent with the proposed structures.
The mode of coordination of one of these compounds was
conﬁrmed by X-ray diffraction. Crystals suitable for structure
determination were grown by slow diffusion of diethyl ether into a
MeOH/CH2Cl2 (80:20 v/v %) solution [38]. The compound crystallizes
in the monoclinic space group C2/c as its chloride salt alongside one
molecule of methanol. An ORTEP drawing [39] with the corresponding
atom labelling scheme is presented in Fig. 1 together with the selected
bond lengths and angles.
The molecular structure conﬁrms coordination of the thiosemi-
carbazone ligand by the rutheniummetal through the imine nitrogen
and thione sulfur donor atoms in a bidentate fashion forming a ﬁve-
membered chelate ring. This N,S-coordination mode is the most
common for thiosemicarbazone ligands, however N,S-coordination in
which a four-membered chelate ring is formed has been as well
observed [40–44]. The complex adopts the commonly observed
piano-stool geometry of many half-sandwich arene ruthenium(II)
complexes [29,37,44–46]. In this case, the p-cymene ring forms the
seat of the piano-stool, while the bidentate thiosemicarbazone (N,S)
and the chlorido ligand form the three legs of the stool. Intermolecular
distances of 2.969(8) Å between Cl(2) and N(1) as well as 3.146(5) Å
between N(1) and O(1) of the solvated methanol molecule are
indicative of strong hydrogen bonding (Fig. 2). The ruthenium center
adopts a pseudo-tetrahedral geometry as the p-cymene ligand
essentially occupies one coordination site. Bond angles of 81.82(12),
83.45(12) and 86.52(5)° are observed for N(3)-Ru(1)-S(1), N(3)-Ru
(1)-Cl(1) and S(1)-Ru(1)-Cl(1), respectively. On closer examination
of the bond lengths, it appears that the p-cymene ligand is
asymmetrically coordinated to the metal center as the Ru-Carene
bond lengths are slightly varied from 2.162(5) for Ru(1)-C(10) to
2.266(6) Å for Ru(1)-C(12). This is also observed for a similar
anthraldehyde TSC ruthenium complex [29]. It is believed that this
distortion may minimize steric interaction between the p-cymene
moiety and the thiosemicarbazone ligand [29].
Complexes 1–4 alongwith their corresponding ligands (L1 and L2)
were evaluated for their cytotoxic potencies against WHCO1
oesophageal cancer cells [47]. This was carried out by means of a
colorimetric MTT assay and the IC50 values obtained are listed in
Scheme 1. Synthesis of mononuclear (η6-arene) ruthenium(II) thiosemicarbazone complexes (1 and 2).
2
Table 1. Two complexes (1 and 4) displayed moderate cytotoxicity
against this particular cell line. Complex 4 displayed the best activity
(IC50=8.96 μM), however, in comparison to its free ligand, a decrease
in potency is observed. The low activity may be attributed to
inadequate accumulation of these compounds inside the cells. Low
in vitro cytotoxic activity has often been observed for ruthenium
compounds, including NAMI-A. In this case of NAMI-A, the compound
displays low in vitro activity but increased activity against tumour
metastases in vivo. Many other ruthenium compounds have been
found to display enhanced cytotoxicity in vivo despite low in vitro
activity [21,22]. In this case further tests in vivomay reveal promising
results.
In conclusion, twomono- and two dinuclear (η6-arene) ruthenium
(II) thiosemicarbazone complexes have been prepared and charac-
terized using standard spectroscopic and analytical techniques. Single
crystal X-ray diffraction conﬁrmed coordination of the thiosemicar-
bazone in a bidentate N–Smanner to ruthenium, resulting in a pseudo
tetrahedral geometry about the metal center. Two complexes
displayed moderate activity against WHCO1 cells.
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Scheme 2. Synthesis of dinuclear (η6-arene) ruthenium(II) thiosemicarbazone complexes (3 and 4).
Fig. 1. Molecular structure of cation 1 at 50% probability level with chloride anion and
methanol molecule omitted for clarity. Selected bond lengths (Å) and angles (°): Ru(1)-
Cl(1) 2.4004(15), Ru(1)-S(1) 2.3579(15), Ru(1)-N(3) 2.131(4), C(1)-S(1) 1.695(6), C
(1)-N(1) 1.314(7), C(1)-N(2) 1.338(6), N(2)-N(3) 1.400(6), C(2)-N(3) 1.285(6); Cl(1)-
Ru(1)-S(1) 86.52(5), Cl(1)-Ru(1)-N(3) 83.45(12), S(1)-Ru(1)-N(3) 81.82(12), N(1)-C
(1)-S(1) 121.8(4), S(1)-C(1)-N(2) 120.7(5), N(1)-C(1)-N(2) 117.5(5), N(2)-N(3)-C(2)
113.6(4). Fig. 2. Hydrogen bonded network in [1]Cl · MeOH.
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Compound IC50 (μM) a 95% Conﬁdence Interval
L1 N200 not applicable
L2 0.21 0.11–0.38
1 81.13 69.87–94.21
2 N200 not applicable
3 N200 not applicable
4 8.96 1.26–63.78
a Drug concentration required for 50% inhibition of cell viability.
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and kindly provided by Professor Rob Veale (University of Witwatersrand, South
Africa). IC50 determinations were carried out using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 3000 cells were seeded per
well in 96-well plates. Cells were incubated at 37 °C under 5% CO2 (24 hours),
after which aqueous DMSO solutions of each compound (10 μl, with a constant
ﬁnal DMSO concentration of 0.2%) were plated at various concentrations. After a
48 hour incubation period, MTT (10 μl) solution was added to each well. After
further 4 hour incubation, solubilisation solution (100 μl) was added to each well,
and plates were incubated overnight. Plates were read at 595 nm using a BioTek
microplate reader.
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